Search jobs 04-Aug-2021 Abbott Receives FDA Clearance For Its Imaging Technology Using Artificial Intelligence For Vessels in the Heart - Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence
- The new intuitive interface provides step-by-step guidance to enhance ease of use
- When combined with Abbott s Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care
Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company s new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary bl
New-york
United-states
Japan
Ziad-ali
Dematteis-cardiovascular-institute-at-st
Ultreon-software
Linkedin
Facebook
Drug-administration
Heart-center
Artificial-intelligence
Dragonfly-opstar